Company intelligence / Profile preview
Juncell Therapeutics
Shanghai (Jiading District, Anting International Medical Industry Park), Shanghai, Chinajuncell.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
Two clinical-stage TIL therapies have demonstrated promising safety and efficacy in treating ten types of heavily pretreated advanced solid tumors. 7 patients achieved complete response (CR), with the longest being nearly 3 years, with lower intensity pretreatment, no IL-2 infused, and no serious adverse events (SAE) occurring in all patients
- Therapeutic areas
- Oncology
- Modalities
- TIL (Tumor-Infiltrating Lymphocyte) therapiesnon-viral vector-based genetically modified TIL therapies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Juncell Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Juncell Therapeutics.